


FOR EFFECTIVE BOWEL CLEANSING

NOW AVAILABLE
IN THE UK

Trials show nothing comes cleaner^{1,2} than Phospho-soda

"Phospho-soda was graded as 'excellent' or 'good' in 86% of 21 cases for the quality of mechanical bowel preparation, compared with 63% of 19 cases for sodium picosulphate"¹

"Overall, endoscopists scored sodium phosphate as 'excellent' or 'good' in 90% vs. 68% after the polyethylene glycol lavage."²




Fleet Phospho-soda gives you a thoroughly effective way to clean the colon before colonoscopy examination, radiological procedures or surgery.

Fleet Phospho-soda is an oral saline laxative, increasing fluid accumulation in the lumen by osmosis to give bowel movements in 1/2 - 6 hours.

Under clinical conditions, not only did Fleet Phospho-soda outperform sodium picosulphate in bowel cleansing, it was also associated with less abdominal pain in the patients taking it. In addition, with a total dosage of only 90ml, patients found it easier to complete the course when compared with other bowel cleansing preparations.

The trials tell the story again and again - when you require a really clean bowel for medical procedures, you want nothing less than Fleet Phospho-soda.



Fleet™

Phospho-soda™
Oral Solution For Bowel Cleansing

Prescribing information:

Indications: For use as a purgative for bowel cleansing in preparation for surgery or preparing the colon for x-ray or endoscopic examination. **Active ingredients:** Each 45ml bottle (Dosage 2 x 45ml) contains the equivalent of 24.4g (54.3% w/v) Sodium Dihydrogen Phosphate Dihydrate Ph Eur and 10.8g (24.0% w/v) Disodium Phosphate Dodecahydrate Ph Eur per 45ml. Sodium content is 5.0g per 45ml. Excipients: Glycerol, Sodium Saccharin, Sodium Benzoate (E211), Ginger-Lemon flavouring, Purified water. Fleet Phospho-soda is sugar-free. **Dosage: Adults only:** Unless directed by a physician, Fleet Phospho-soda should be taken in the morning and in the evening on the day before examination or surgery. **Note: No solid foods may be taken for breakfast, lunch or evening meal on the day of taking this medicine. The liquid "diet" indicated should be strictly adhered to. 1st Dose - At 7 a.m. (morning) on the day before examination or surgery:** Dilute total contents of one bottle (45ml) in half a glass (120ml) of cool water. Drink this solution, followed by one full glass (240ml) of cool water. At mid-day, follow with at least three full glasses (720ml) of water or "clear liquid", more if desired. "Clear liquids" include water, clear soup, strained fruit juices without pulp, black tea or black coffee, clear carbonated and non-carbonated soft drinks. **2nd Dose - At 7 p.m. (evening) on the day before examination or surgery:** Dilute total contents of the second bottle (45ml) in half a glass (120ml) of cool water. Drink this solution followed by one full glass (240ml) of cool water. Additional "clear liquid" may be taken up until midnight if necessary. This product normally produces a bowel movement in 1/2 to 6 hours. **NOT TO BE GIVEN TO CHILDREN. DO NOT USE** when nausea, vomiting or abdominal pain is present, unless directed by a physician. **Contra Indications:** The product is contra indicated in patients with known or suspected gastrointestinal obstruction or ileus. Do not use in patients with congestive heart failure, Hirschsprung's Disease or congenital megacolon. **Warnings:** Use with caution in patients with impaired renal function, heart disease, colostomy or on a low salt diet as hyperphosphataemia, hypocalcaemia, hypernatraemic dehydration and acidosis may occur. Patients should be warned to expect frequent, liquid stools. **Interactions:** Use with caution in patients taking calcium channel blockers, diuretics, lithium treatment or other medication that might affect electrolyte levels as hyperphosphataemia, hypocalcaemia, hypernatraemic dehydration and acidosis may occur. **Use in Pregnancy and Lactation:** Use under medical supervision only. **KEEP OUT OF REACH OF CHILDREN. Full prescribing information is available on request. Pharmaceutical Precautions:** Store below 25°C. Do not refrigerate. **Legal Category:** P. **Package Quantities:** Two single dose bottles, each containing 45ml of solution in a single carton. **Product Licence Number:** 0083/0044. **Product Licence Holder:** E.C. De Witt & Co. Ltd., a subsidiary of C.B. Fleet Company Inc. USA. For further information, please contact the Marketing Department at the address below. Fleet Phospho-soda (2 x 45ml) N.H.S. Price £4.79.

References

1. Data on file, E.C. De Witt & Co. Ltd. 1995.
2. Cohen S.M. et al., Prospective, Randomised, Endoscopic-blinded Trial comparing Precolonoscopy Bowel Cleansing Methods. Dis. Colon Rectum, July 1994, 37, No.7, 689-696.

SEND NOW FOR YOUR FREE
FLEET PHOSPHO-SODA FACT PACK

Simply complete and cut out the coupon and return it to: The Marketing Department, E.C. De Witt & Co. Ltd., FREEPOST (WA1476), Runcorn, Cheshire, WA7 1BR.


NAME

JOB TITLE

ADDRESS

..... POST CODE

SIGNATURE



COLIFOAM

10% hydrocortisone acetate

FIRST CLASS TREATMENT WHICH TRAVELS TO WORK

- ☞ Colifoam is highly effective for distal ulcerative colitis.⁽¹⁾
- ☞ The retrograde spread of Colifoam increases with the extent of disease.⁽²⁾
- ☞ Colifoam is easier to retain than liquid enemas and causes less interference with social, sexual and occupational activities.^(1,3)

PRESCRIBED WITH CONFIDENCE FOR OVER 20 YEARS.



PRESCRIBING INFORMATION: **Presentation:** White odourless aerosol containing hydrocortisone acetate PhEur 10% w/w. **Uses:** Ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration:** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). **Contra-indications, warnings etc:** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety

during pregnancy has not been fully established. Although uncommon at this dosage, local irritation may occur. **Pharmaceutical precautions:** Pressurised container containing flammable propellant. Protect from sunlight and do not expose to temperatures above 50°C. Keep away from sources of ignition. Do not pierce or burn even after use. Do not refrigerate, store below 25°C. Keep out of reach of children. For external use only. **Legal category:** POM. **Package quantity & basic NHS cost:** 20.8g canister plus applicator, £7.07. Provides approximately 14 doses. **Product Licence no:** 0036/0021. **References:** 1. Somerville KW *et al.* BMJ 1985;291:866. 2. Farthing MJG *et al.* BMJ 1979;2:822-824. 3. Ruddell WSJ *et al.* Gut 1980;21:885-889. Further information is available on request from Stafford-Miller Ltd., Broadwater Road, Welwyn Garden City, Herts. AL7 3SP. **Code:** DO2665.



Pylorid Prescribing Information.

Indications Treatment of duodenal and benign gastric ulcer. *H. pylori* eradication and prevention of duodenal ulcer relapse when given with clarithromycin or amoxicillin. **Dosage Adults:** duodenal ulcer 400mg twice daily for four weeks. Treatment may

be extended for further four weeks. Benign gastric ulcer 400mg twice daily for eight weeks. *H. pylori*-associated duodenal ulcer 400mg twice daily with amoxicillin 500mg four times daily (2g) or clarithromycin 250mg four times daily or 500mg three times daily (1g-1.5g) for first two weeks of treatment then Pylorid 400mg twice daily for further two weeks. **Children:** Not currently recommended. **Contra-indications** Known hypersensitivity to any

of the ingredients. **Precautions** In gastric ulcer exclude malignancy before treatment. Plasma levels increased in renal impairment and elderly. Avoid use in extreme renal impairment (see data sheet). Avoid in patients with history of acute porphyria. As contains bismuth not recommended for maintenance use or more than 16 weeks in a year. See prescribing information for amoxicillin or clarithromycin before

 **Glaxo** Pharmaceuticals UK Limited

“ANY LAST REQUESTS H. PYLORI?”

Combine new Pylorid with clarithromycin and you've a powerful weapon against H. pylori. And, when H. pylori is eradicated, duodenal ulcers are unlikely to return.

**WHEN ERADICATING
H. PYLORI**

PYLORID™

RANITIDINE BISMUTH CITRATE



PRESCRIBE WITH CLARITHROMYCIN

co-prescribing. **Side Effects** Blackening of tongue and stools. Rarely hypersensitivity reactions including pruritus, skin rash, anaphylaxis. Gastrointestinal upsets including diarrhoea, abdominal discomfort, gastric pain. Headache. Transient changes in liver enzymes SGPT (ALT), SGOT (AST). Mild anaemia. Ranitidine-related side-effects (relevance to use of Pylorid *unknown*): Dizziness. Rarely, reversible mental confusion usually

in ill or elderly patients. Occasional hepatitis. Rarely, acute pancreatitis, arthralgia, myalgia. Rare cases of leucopenia, thrombocytopenia, usually reversible. Agranulocytosis and pancytopenia. Rare cases of erythema multiforme. Rare reports of breast symptoms in men. As with other H₂-receptor antagonists rare cases of bradycardia, A-V block and asystole. **Presentations** Pylorid tablets each containing 400mg of ranitidine bismuth

citrate. (Product licence number 14213/0001). 28 Tablets £26.00. 56 Tablets £52.00. **Product licence holders** Glaxo Group Ltd, Greenford Road, Greenford UB6 0HE. **POM** Pylorid is a Glaxo trade mark. Further information is available on request from: Glaxo Pharmaceuticals UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Telephone 0181-990 9444. Date of preparation: August 1995.

STAY HEALED[†]



NOW APPROVED IN MAINTENANCE

15mg ZOTON[▼]

Lansoprazole

[†] Up to 87% remission rate in reflux oesophagitis after 1 year. (Range 69-87%)¹⁻⁴

ZOTON[▼] Lansoprazole: Abbreviated Prescribing Information
Presentation: Two tone lilac/purple hard gelatin capsule containing 30 mg lansoprazole, yellow hard gelatin capsule containing 15 mg lansoprazole as enteric coated granules.
Indications: Healing and maintenance of duodenal ulcer, and gastro-oesophageal reflux disease (GORD), healing of benign gastric ulcer, and reflux oesophagitis. Also benign peptic lesions including reflux oesophagitis unresponsive to H₂ receptor antagonists.
Dosage and Administration: Lansoprazole should be administered once daily. *Duodenal ulcer:* 30 mg daily for 4-8 weeks, then 15 mg for maintenance dose. *Reflux oesophagitis:* 30 mg daily for 4-8 weeks, then 15 mg for maintenance dose. *Benign gastric ulcer:* 30 mg daily for 8 weeks. The maintenance dose in GORD can be increased to 30 mg depending on patient response. Do not chew or crush capsules. Swallow whole. No dosage adjustment is necessary in the elderly, or patients with renal or hepatic impairment. There is no experience with Lansoprazole in children. **Contra-indications:** No known contra-

indications to Lansoprazole. **Precautions:** As with other anti-ulcer therapies the possibility of malignancy should be excluded when gastric ulcer is suspected. **Pregnancy and Lactation:** There is no experience with the use of lansoprazole in pregnancy, and its use should be avoided. Animal studies indicate Lansoprazole is excreted into breast milk, there is no information on secretion into breast milk in humans. Breast feeding should be discontinued if the use of Lansoprazole is considered essential. **Side effects:** Generally transient and self limiting, including gastro-intestinal disturbances, headache, dizziness, dry mouth, fatigue, rashes, depression and increases in liver function tests. Arthralgia, peripheral oedema, and haematological changes have been reported rarely. **Legal Category:** POM. **Package Quantities:** 30mg capsules: Blister packs of 56, 28, 14 and 7 (hospital starter pack) capsules. 15mg capsules: Blister packs of 56, and 28. **Product Licence No:** PL 0095/0264 30mg capsules. PL 0095/0302 15mg capsules. **Cost:** 30mg capsules: 7 £9.09 (hospital starter pack), 14 £18.18, 28 £33.36, 56 £66.72. 15mg capsules: 28 £18.80, 56 £37.60.

Full prescribing information is available on request. **Product Licence Holder:** Cyanamid of Great Britain Ltd, Fareham Road, Gosport, Hants PO13 0AS. Date of preparation; Jan 1996
REFERENCES: 1. Gough, A.L., *Gut*, 1994, 35 (Suppl 5) (101756) 2. Hatlebakk, J.G., and Berstad, A., *Gastroenterol*, 1995, 108 (4), A111 (102909) 3. Poynard, T. et al, *Gastroenterol*, 1995, 108 (4), A195 (102907) 4. Robinson, M., and Lanza F. et al, *Gastroenterol*, 1994, 106 (4), Pt 2 (101495).

Full prescribing information is available on request.

* Trademark of Takeda Chemical Industries Ltd.



Under Licence agreement with Takeda Chemical Industries Ltd, Japan.



Further information can be obtained from: Wyeth Laboratories, Huntercombe Lane South, Taplow, Maidenhead, Berks SL6 0PH



ZZ0T473

EVERYDAY PEOPLE TAKE LOSEC.

LOSEC® CAPSULES (omeprazole) ABBREVIATED PRESCRIBING INFORMATION (refer to full data sheet before prescribing)

PRESENTATION: LOSEC Capsules containing 10mg, 20mg or 40mg omeprazole (O) as enteric coated granules with an aqueous based coating. **USES:** Oesophageal reflux disease. Duodenal and benign gastric ulcers (including NSAID-induced). *Helicobacter pylori* eradication: Relief of associated dyspeptic symptoms in combination treatment with antibiotics. Prophylaxis of acid aspiration. Zollinger-Ellison syndrome. **DOSAGE & ADMINISTRATION:** **Adults (including the elderly):** The usual dose in oesophageal reflux disease and peptic ulcer is 20mg once daily, increasing to 40mg once daily in severe or refractory cases, if required. **Oesophageal reflux disease:** Healing: 20mg daily for 4 weeks. Continue for further 4-8 weeks if required. **Maintenance in acid reflux disease:** LOSEC 10mg daily. Increase to 20mg daily if symptoms return. **Duodenal ulcer (DU):** Healing: 20mg daily for 4 weeks. **DU maintenance:** LOSEC 10mg daily increasing to 20mg daily if symptoms return. **Benign Gastric Ulcer:** 20mg daily for 8 weeks. **Helicobacter pylori eradication: DU disease: Triple therapies:** LOSEC 40mg daily with amoxicillin (A) 500mg and metronidazole (M) 400mg, both three times a day for 1 week. Or clarithromycin (C) 250mg and metronidazole 400mg (or tinidazole 500mg) both bd for 1 week. **Dual therapies:** LOSEC 40mg daily

with amoxicillin 750mg to 1g bd or clarithromycin 500mg tid, both for 2 weeks. **GU disease:** LOSEC 40mg daily with amoxicillin 750mg to 1g bd for 2 weeks. **Prophylaxis of acid aspiration:** LOSEC 40mg on the evening before surgery followed by LOSEC 40mg on the morning of surgery. **Zollinger-Ellison Syndrome:** 60mg daily as long as clinically indicated. Individually adjust within range 20-120mg daily. If in excess of 80mg daily give in 2 equal divided doses. **Renal impairment:** No dose adjustment needed. **Hepatic impairment:** Adjust dose (maximum daily dose 20mg). **Children:** No experience of use. **CONTRA-INDICATIONS, WARNINGS, etc:** No known contra-indications. In gastric ulcer, exclude malignancy before starting therapy. Avoid in pregnancy unless no safer alternative. Discontinue breast feeding if LOSEC is considered essential. **Side effects:** LOSEC is well tolerated. Adverse reactions are generally mild and reversible (relationship to LOSEC not established in many cases). They include diarrhoea, headaches, skin disorders and in isolated cases, angioedema, musculoskeletal disorders, fatigue, insomnia, dizziness, blurred vision, dry mouth, vertigo, paraesthesia, liver enzyme and haematological changes. **Interactions:** LOSEC can delay the elimination of diazepam, phenytoin and warfarin. Plasma concentrations of omeprazole and clarithromycin are increased when used concomitantly. Simultaneous treatment with omeprazole and digoxin may increase the bioavailability of digoxin. **PHARMACEUTICAL**

PRECAUTIONS: Use within three months of opening. Store below 30°C. Replace cap firmly after use. Dispense in original container. **LEGAL CATEGORY:** POM. **FURTHER INFORMATION:** *Helicobacter pylori* (Hp) is associated with acid peptic and ulcer disease, contributing to gastritis and ulcer recurrence. Eradication of Hp with omeprazole and antibiotics gives rapid symptom relief, high healing rates and long-term remission of ulcer disease. **Quality of life:** In recent clinical data, in patients with acute peptic ulcer disease, omeprazole Hp eradication therapy improved patients' quality of life. **PACKAGE QUANTITIES:** 10mg: bottles of 7* capsules £4.99, bottles of 28 capsules £19.95. 20mg: bottles of 7* capsules, £8.86, bottles of 28 capsules, £35.45; 40mg: bottles of 7* capsules £17.72, bottles of 14 capsules £35.45. (*Hospital pack only). **MARKETING AUTHORIZATION NO:** PL 0017/0337. LOSEC Capsules 10mg. PL 0017/0238 - LOSEC Capsules 20mg. PL 0017/0320 - LOSEC Capsules 40mg.



For further information contact the **MARKETING AUTHORIZATION HOLDER:** Astra Pharmaceuticals Ltd, Home Park, Kings Langley, Herts WD4 8DH. Tel: (01923) 266191. LOSEC is a registered trademark of Astra Pharmaceuticals Ltd. **Date of preparation:** January 1996. LOS/ADV 847



PRESCRIBING INFORMATION:

Indications Duodenal ulcer (including those associated with *H. pylori* infection), benign gastric ulcer, postoperative ulcer, oesophageal reflux disease, Zollinger Ellison Syndrome, prophylaxis of gastrointestinal haemorrhage from stress ulcer, recurrent haemorrhage from bleeding peptic ulcer, acid aspiration (Mendelson's Syndrome). Tablets, Syrup, Effervescent Tablets only, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), prevention of NSAID-associated duodenal ulcer, chronic episodic dyspepsia, severe oesophagitis, long-term management of healed oesophagitis. **Dosage Adults:** Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. In duodenal ulcer, 300mg twice daily produces higher healing rates at four weeks. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Duodenal ulcers associated with *H. pylori*, 300mg at bedtime or 150mg twice daily with oral amoxicillin 750mg three times daily and metronidazole 500mg three times daily for 2 weeks. Zantac therapy then continued for a further 2 weeks. Ulcers following non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Prevention of NSAID-associated duodenal ulcer: 150mg twice daily concomitantly with NSAID therapy. Chronic episodic

dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Moderate to severe oesophagitis: 150mg four times daily for up to twelve weeks. Long-term treatment of healed oesophagitis: 150mg twice daily. Obstetric patients at commencement of labour; oral dose of 150mg may be followed by 150mg at six-hourly intervals (see data sheet). Those at risk of acid aspiration syndrome; oral dose of 150mg two hours before induction of general anaesthesia with preferably 150mg the previous evening. Alternatively, Zantac Injection 50mg intramuscularly or by slow intravenous injection 45 to 60 minutes before general anaesthesia. Zantac Injection may be given every six to eight hours either as slow (over a period of at least two minutes) intravenous injection of 50mg, after dilution to a volume of 20ml per 50mg dose, or as intermittent intravenous infusion at a rate of 25mg per hour for two hours; alternatively, as intramuscular injection of 50mg (2ml) every six to eight hours. Prophylaxis of haemorrhage from stress ulceration or from bleeding peptic ulceration: parenteral administration may be continued until oral feeding commences. If still at risk, Zantac Tablets or Syrup 150mg may be given twice daily. Prophylaxis of haemorrhage from stress ulceration: priming dose of 50mg as a slow intravenous injection followed by continuous intravenous infusion of 0.125 to 0.250mg/kg/hr

redible

Zantac

RANITIDINE HCl

More than 550 million
prescriptions have been written
for Zantac* worldwide¹

may be preferred. **Children:** Oral dose for peptic ulcer: 2mg/kg to 4mg/kg, twice daily to a maximum of 300mg per day. **Contra-indications** Patients with known hypersensitivity to ranitidine. **Precautions** Caution when using Effervescent Tablets in sodium-restricted patients. Exclude malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients taking NSAIDs concomitantly with Zantac recommended, especially if elderly. Protects against NSAID-associated ulceration in duodenum and not in stomach. Reduce dosage in the presence of severe renal failure (see data sheet). Avoid in patients with history of porphyria. Effervescent Tablets contain aspartame, use with caution in patients with phenylketonuria. Rapid administration of injection may rarely cause bradycardia; recommended rates of administration should not be exceeded. Like other drugs, use during pregnancy and lactation only if strictly necessary. **Side effects** Headache, dizziness, skin rash, occasional hepatitis, rarely arthralgia, myalgia, and with antibiotics, diarrhoea. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock, rare cases of breast symptoms in men. As with other H₂-receptor antagonists rare cases of bradycardia, A-V block

and asystole (see data sheet). **Presentations** Zantac 150 Tablets each containing 150mg ranitidine HCl, (Product licence number 10949/0042, 60 tablets £27.89); Zantac 300 Tablets each containing 300mg ranitidine HCl (Product licence number 10949/0043, 30 tablets £27.43); Zantac Effervescent Tablets each containing 150mg ranitidine HCl and 14.3mEq sodium, (Product licence number 10949/0137, 60 tablets £27.89); Zantac Effervescent Tablets each containing 300mg ranitidine HCl and 20.8mEq sodium (Product licence number 10949/0138, 30 tablets £27.43); Zantac Syrup each 10ml dose containing 150mg ranitidine HCl (Product licence number 10949/0108, 300ml bottle £22.32); Zantac Injection each 2ml dose containing 50mg ranitidine HCl (product licence number 10949/0109, 5 x 2ml £3.21). **Product licence holders** Glaxo Pharmaceuticals UK Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. **POM** Zantac is a Glaxo trade mark. Further information is available on request from Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Telephone 0181-990 9444. Date of preparation: September 1995.


*As 'Zantac' or other licensed ranitidine brands.

Reference

1. Data on file. I.M.S.

Glaxo

**Prescribing information
Klaricid 500**

Presentation: Yellow ovaloid film coated tablets containing 500mg of clarithromycin. Each tablet is engraved with  on one side. **Indications:** Klaricid in the presence of acid suppression effected by omeprazole is indicated for the eradication of *H. pylori* in patients with duodenal ulcers.

Dosage and Administration: Adults: Clarithromycin 500mg t.d.s. for 14 days plus oral omeprazole 40mg o.d. The pivotal study was carried out with omeprazole 40mg o.d. for 28 days, whilst supportive studies were carried out with omeprazole 40mg o.d. for 14 days. See omeprazole data sheet for further information on omeprazole dosing. **Contra-**

indications, Warnings etc: **Contraindications:** Known hypersensitivity to macrolide drugs. Do not administer with ergot derivatives. **Precautions:** Caution in adults with impaired hepatic and renal function. Do not administer to paediatric patients with hepatic or renal failure. Prolonged or repeated use of clarithromycin may result in an overgrowth of non-susceptible bacteria or fungi. If superinfection occurs, clarithromycin should be discontinued and appropriate therapy instituted. Caution in patients taking drugs metabolised by the cytochrome P450 system as there may be elevations in their serum levels. *H. pylori* organisms may develop resistance to clarithromycin in a small number of patients.

Interactions: Potentiation of terfenadine, astemizole, theophylline, digoxin, warfarin and carbamazepine. Interaction of Klaricid tablets with simultaneously administered zidovudine in adults. No interaction with oral contraceptives. **Side-effects:** Klaricid is generally well tolerated. Side-effects include nausea, vomiting, diarrhoea and rarely pseudomembranous colitis, abdominal pain, headache, taste perversion, reversible tongue discoloration, glossitis and stomatitis. Allergic reactions including anaphylaxis and Stevens-Johnson syndrome, and transient central nervous system side-effects have been reported. Hepatic dysfunction has also been reported. **Use**

in Pregnancy and Lactation: The safety of Klaricid during pregnancy and breast feeding has not been established, and therefore if a patient becomes pregnant Klaricid should only be used if benefits outweigh risks. Clarithromycin has been found in the milk of lactating animals and humans.

Overdose: Should be treated with gastric lavage and supportive measures. **Basic NHS Price:** £4.82 per day. **Legal Category:** POM. **Marketing Authorisation Number:** PL 0037/0254: 42 tablet calendar blister pack. Further information is available on request from Abbott Laboratories Ltd., Norden Road, Maidenhead, Berkshire SL6 4XE. Date of Preparation December 1995.

 **ABBOTT
ANTIBIOTICS**

PXKHP95333



OUR WORLD
IS CHANGING FOR GOOD.
ULCER TREATMENT
IS CHANGING FOR GOOD.

KLARICID[®] 500
Clarithromycin

CONSISTENTLY HIGH
ERADICATION OF *H. PYLORI*.*

* Klaricid 500mg t.d.s. plus omeprazole 40mg o.d.



Micro
Medical

If measuring Hydrogen levels raises big concerns...




Here's a small suggestion

The Micro H₂ is a powerful diagnostic tool for measuring expired Hydrogen concentrations in ppm. Measurements are easily obtained from either tidal breathing or a single expiration. These results are then displayed on the large, easy to read, liquid crystal display. The Micro H₂ is extremely portable and offers simple operation for use with babies, children and adults.

Features


- Small, lightweight and portable
- Supplied with all accessories in a sturdy carrycase
- Auto-Zero facility
- Easy to use, clean and maintain
- Automatic sensor drift detection
- Simple calibration routine
- 1.0ppm sensitivity
- Zero warm up time



Micro Medical Limited
The Admiral's Offices The Chatham Historic Dockyard Chatham Kent ME4 4TQ
Telephone 01634 843383 Fax 01634 830814 International fax + 44 1634 830814
CompuServe 100 565.3321 E mail sales@micromed.co.uk Home page <http://www.micromed.co.uk>

This woman

HAS HEPATITIS C



Do you tell her

IT COULD BE FATAL?

85,000 people in the UK
have chronic HCV*



50,000 of them will
develop cirrhosis*



10,000 will develop
liver cancer*



Many will die
prematurely



She could be one of them



Viraferon is not a vaccine,
nor a miracle cure.
But should this patient
develop chronic HCV
it could save her life.

VIRAFERON
INTERFERON ALFA-2B (rbe)



Today, for the future

* Estimates based on current incidence and epidemiology of hepatitis C ^{1,2}

PRESCRIBING INFORMATION

For full prescribing information please refer to full Data Sheet for Viraferon 25 million IU vial or 10 million IU vial.

Uses: Treatment of chronic hepatitis B infection. Uses: Treatment of chronic hepatitis B infection. Disease activity is assessed by ALT levels. **Non-B:** Dose and duration of treatment are 3 million IU three times a week for 18 months. **Non-A:** Dose and duration of treatment are 3 million IU three times a week for up to 18 months. **Chronic hepatitis C/Non-A:** Dose and duration of treatment are 3 million IU three times a week for up to 18 months. **Chronic hepatitis C/Non-B:** Dose and duration of treatment are 3 million IU three times a week for up to 18 months. **Chronic hepatitis C/Non-A/Non-B:** Dose and duration of treatment are 3 million IU three times a week for up to 18 months. **Chronic hepatitis C/Non-A/Non-B/Non-C:** Dose and duration of treatment are 3 million IU three times a week for up to 18 months.




Contraindications: A history of hypersensitivity to interferon Alfa-2B or to any of the excipients. **Warnings:** Viraferon may cause depression, suicidal thoughts, and suicidal behaviour. Patients with a history of depression should be monitored closely. **Precautions:** Patients with a history of depression should be monitored closely. **Side Effects:** Common side effects include flu-like symptoms, fatigue, and weight loss. **Contraindications:** A history of hypersensitivity to interferon Alfa-2B or to any of the excipients. **Warnings:** Viraferon may cause depression, suicidal thoughts, and suicidal behaviour. Patients with a history of depression should be monitored closely. **Precautions:** Patients with a history of depression should be monitored closely. **Side Effects:** Common side effects include flu-like symptoms, fatigue, and weight loss.

Dosage in hepatitis C:
3M IU
three times a week
for up to 18 months

© Schering-Plough January 1996

Schering-Plough

Statistics books you can count on



Statistics at Square One 9th Edition

T D V Swinscow,
revised by **M J Campbell**

This step-by-step guide has helped thousands of readers get to grips with the basic tools of statistics. Now completely revised and expanded it remains the essential primer for students and specialists alike.

- Includes new chapters on survival analysis and design of studies
- Uses examples from medicine to illustrate techniques, such as the 2 test, non-parametric tests and correlation
- Describes the newer techniques, such as stem and leaf plots, box-whisker plots and unequal variance t-tests
- Answers all of the common questions about statistics and offers exercises for self-testing

January 1996 152 pages
UK £8.95; Overseas £11.00
(BMA members £7.95; £10.00)

Statistics in Clinical Practice

David Coggon

Statistics in Clinical Practice is a practical, easy to read guide to demystifying statistics which will show you how to interpret data and present statistical information yourself.

- Covers all the basic principles including probability, making conclusions based on statistical results and summarising data
- Contains realistic clinical examples
- Assumes only a basic knowledge of mathematics
- Includes useful question and answer sections to test yourself

128 pages 1994
UK £10.95; Overseas £12.95
(BMA members £9.95; £12.00)

Medical Statistics on Personal Computers

R A Brown, J Swanson Beck

Explains how to get the best out of software available for analysing statistical data on PC's.

160 pages Second edition 1994
UK £10.95; Overseas £13.00
(BMA members £9.95; £12.00)

Statistics with Confidence

**Martin J Gardner,
Douglas C Altman**

Gives reasons for using confidence intervals, followed by detailed methods of calculation, including numerous worked examples and specially compiled tables.

156 pages 1989
UK £9.95; Overseas £11.00
(BMA members £8.95; £10.00)

Confidence Interval Analysis (CIA)

Martin J Gardner, Stephen B Gardner, Paul D Winter

This microcomputer disk with manual can be used alone or with *Statistics with Confidence*.

Software is available for IBM compatibles on either 51/4 or a 31/2 inch disk.

82 pages 1989
UK £65.00 Educational establishments, research institutes and the NHS; £45.95 (inc VAT)

Statistics in Practice

Sheila M Gore, Douglas G Altman

107 pages 1982
UK £9.95; Overseas £11.00
(BMA members £7.95; £10.00)

Order form

Available from: BMJ Publishing Group, P.O. Box 298, London WC1H 9HE
Telephone: 0171-2763744 Fax: 0171-2763745 Telex: 2763745 (BMJ) BMA House

Qty	Title	Amount
	Statistics at Square One 9th Edition	
	Statistics in Practice	
	Medical Statistics on Personal Comp.	
	Statistics with Confidence	
	Confidence Interval Analysis	
	Statistics in Practice	
	Total	

Name _____

Address _____

Postcode _____

BMA Membership No. _____

Cheque enclosed (made payable to British Medical Journal)

£ _____

Debit my American Express/Visa/Mastercard

Card No. _____

Expires _____

Signature _____

Please send me a BMJ Publishing Group catalogue

ALL THE STRENGTHS OF 'ASACOL', NOW AVAILABLE IN FOAM.

Prescribing Information: Presentation 'Asacol' Tablets, PL 0002/0173, each containing 400 mg mesalazine (5-aminosalicylic acid) coated with a pH-dependent acrylic based resin (Eudragit S) formulated to release the active ingredient in the terminal ileum and colon. Blister packs of 120 (12 x 10), £39.62. 'Asacol' Suppositories 250 mg, PL 0002/0158, each containing 250 mg mesalazine. 20, £6.50. 'Asacol' Suppositories 500 mg, PL 0002/0195, each containing 500 mg mesalazine. 10, £6.50. 'Asacol' Foam Enema, PL 0002/0222, 1 g mesalazine per metered dose. Carton containing can of 14 metered doses, 14 disposable applicators and 14 disposable plastic bags. £39.60. **Uses:** For the treatment of mild to moderate acute exacerbations of ulcerative colitis. Tablets and Suppositories for the maintenance of remission of ulcerative colitis. The suppositories and foam enema are particularly appropriate in patients with distal disease. **Dosage and administration: Adults: Tablets: Acute disease:** Six tablets a day in divided doses, with concomitant corticosteroid therapy where clinically indicated. **Maintenance therapy:** Three to six tablets a day in divided doses. **Suppositories: 250 mg suppositories:** Three to six suppositories a day, in divided doses, with the last dose at bedtime. **500 mg suppositories:** A maximum of three suppositories a day, in divided doses, with the last dose at bedtime. **Foam Enema:** For disease affecting the rectosigmoid region, one metered dose 1 g a day for 4-6 weeks; for disease involving the descending colon, two metered doses 2 g once a day for 4-6 weeks. **Children:** There is no dosage recommendation. **Contra-indications:** A history of sensitivity to salicylates or renal sensitivity to sulphasalazine. Severe renal impairment (GFR <20 ml/min). Children under 2 years of age. **Precautions:** Renal disorder: mesalazine is excreted rapidly by the kidney, mainly as its metabolite, N-acetyl-5-aminosalicylic acid. In rats, large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. 'Asacol' is best avoided in patients with established renal impairment but, if necessary, it should be used with caution. Serious blood dyscrasias have been reported very rarely with mesalazine. Haematological investigations should be performed if the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat. Treatment should be stopped if there is suspicion or evidence of blood dyscrasia. 'Asacol' Tablets should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine. **Use in pregnancy and lactation:** No information is available with regard to teratogenicity; however, negligible quantities of mesalazine are transferred across the placenta and are excreted in breast milk following sulphasalazine therapy. Use of 'Asacol' during pregnancy should be with caution, and only if, in the opinion of the physician, the potential benefits of treatment are greater than the possible hazards. 'Asacol' should, unless essential, be avoided by nursing mothers. **Elderly:** Use in the elderly should be cautious and subject to patients

having a normal renal function (see **Precautions**). **Adverse reactions:** The side effects are predominantly gastrointestinal, including nausea, diarrhoea and abdominal pain. Headache has also been reported. Mesalazine may be associated with an exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine. There have been rare reports of leucopenia, neutropenia, agranulocytosis, aplastic anaemia and thrombocytopenia, pancreatitis, hepatitis, allergic lung reactions, lupus erythematosus-like reactions and rash (including urticaria), interstitial nephritis and nephrotic syndrome with oral mesalazine treatment, usually reversible on withdrawal. Renal failure has been reported. Mesalazine-induced nephrotoxicity should be suspected in patients developing renal dysfunction during treatment. Other side effects observed with sulphasalazine such as depression of sperm count and function, have not been reported with 'Asacol'. **Treatment of overdose:** Following tablet ingestion, gastric lavage and intravenous transfusion of electrolytes to promote diuresis. There is no specific antidote. **Legal category:** POM. **Further information:** Whilst mesalazine is known to be the active component of sulphasalazine in the treatment of ulcerative colitis, the other component of sulphasalazine, sulphapyridine, is thought to be responsible for the majority of side effects. 24.6.95.

Smith Kline & French Laboratories, Welwyn Garden City, Hertfordshire AL7 1EY. Authorised user of the trade mark 'Asacol' in the UK. ©1995 Smith Kline & French Laboratories. *Mesalazine is the British approved name of 5-aminosalicylic acid.

ASACOL

MESALAZINE* (5-AMINOSALICYLIC ACID)

FIVE STAR, 5-ASA
COLITIS CONTROL

SB SmithKline Beecham
Pharmaceuticals
Healthy Alliance
partnership beyond prescription



TO YOU IT'S ASACOL.
TO A COLITIC IT MAY MEAN
FREEDOM.

Prescribing Information: **Presentation** 'Asacol' Tablets, PL 0002/0173, each containing 400 mg mesalazine (5-aminosalicylic acid) coated with a pH-dependent acrylic based resin (Eudragit S) formulated to release the active ingredient in the terminal ileum and colon. Blister packs of 120 (12 x 10), £39.62. 'Asacol' Suppositories 250 mg, PL 0002/0158, each containing 250 mg mesalazine. 20, £6.50. 'Asacol' Suppositories 500 mg, PL 0002/0195, each containing 500 mg mesalazine. 10, £6.50. 'Asacol' Foam Enema, PL 0002/0222, 1 g mesalazine per metered dose. Carton containing can of 14 metered doses, 14 disposable applicators and 14 disposable plastic bags. £39.60. **Uses:** For the treatment of mild to moderate acute exacerbations of ulcerative colitis. Tablets and Suppositories for the maintenance of remission of ulcerative colitis. The suppositories and foam enema are particularly appropriate in patients with distal disease. **Dosage and administration: Adults: Tablets: Acute disease:** Six tablets a day in divided doses, with concomitant corticosteroid therapy where clinically indicated. **Maintenance therapy:** Three to six tablets a day in divided doses. **Suppositories: 250 mg suppositories:** Three to six suppositories a day, in divided doses, with the last dose at bedtime. **500 mg suppositories:** A maximum of three suppositories a day, in divided doses, with the last dose at bedtime. **Foam Enema:** For disease affecting the rectosigmoid region, one metered dose 1 g a day for 4-6 weeks; for disease involving the descending colon, two metered doses 2 g once a day for 4-6 weeks. **Children:** There is no dosage recommendation. **Contraindications:** A history of sensitivity to salicylates or renal sensitivity to sulphasalazine. Severe renal impairment (GFR <20 ml/min). Children under 2 years of age. **Precautions:** Renal disorder: mesalazine is excreted rapidly by the kidney, mainly as its metabolite, N-acetyl-5-aminosalicylic acid. In rats, large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. 'Asacol' is best avoided in patients with established renal impairment but, if necessary, it should be used with caution. Serious blood dyscrasias have been reported very rarely with mesalazine. Haematological investigations should be performed if the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat. Treatment should be stopped if there is suspicion or evidence of blood dyscrasia. 'Asacol' Tablets should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine. Use in pregnancy and lactation: No information

is available with regard to teratogenicity; however, negligible quantities of mesalazine are transferred across the placenta and are excreted in breast milk following sulphasalazine therapy. Use of 'Asacol' during pregnancy should be with caution, and only if, in the opinion of the physician, the potential benefits of treatment are greater than the possible hazards. 'Asacol' should, unless essential, be avoided by nursing mothers. **Elderly:** Use in the elderly should be cautious and subject to patients having a normal renal function (see **Precautions**). **Adverse reactions:** The side effects are predominantly gastrointestinal, including nausea, diarrhoea and abdominal pain. Headache has also been reported. Mesalazine may be associated with an exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine. There have been rare reports of leucopenia, neutropenia, agranulocytosis, aplastic anaemia and thrombocytopenia, pancreatitis, hepatitis, allergic lung reactions, lupus erythematosus-like reactions and rash (including urticaria), interstitial nephritis and nephrotic syndrome with oral mesalazine treatment, usually reversible on withdrawal. Renal failure has been reported. Mesalazine-induced nephrotoxicity should be suspected in patients developing renal dysfunction during treatment. Other side effects observed with sulphasalazine such as depression of sperm count and function, have not been reported with 'Asacol'. **Treatment of overdose:** Following tablet ingestion, gastric lavage and intravenous transfusion of electrolytes to promote diuresis. There is no specific antidote. **Legal category:** POM. **Further information:** Whilst mesalazine is known to be the active component of sulphasalazine in the treatment of ulcerative colitis, the other component of sulphasalazine, sulphapyridine, is thought to be responsible for the majority of side effects. 24.6.95.

Smith Kline & French Laboratories, Welwyn Garden City, Hertfordshire AL7 1EY. Authorised user of the trade mark 'Asacol' in the UK. ©1995 Smith Kline & French Laboratories. *Mesalazine is the British approved name of 5-aminosalicylic acid.

ASACOL
MESALAZINE* (5-AMINOSALICYLIC ACID)
FIVE STAR, 5-ASA COLITIS CONTROL

Look, no reflux

(no associated bloating
or belching)

Prepulsid heals oesophagitis by acting
where it's needed – at the oesophagus.¹
Prepulsid relieves heartburn as effectively
as ranitidine and also offers relief of
associated bloating and belching.

A physiological approach

AFTER ANTACIDS TM
Prepulsid
cisapride

PRESCRIBING INFORMATION Indications: GASTRO-OESOPHAGEAL REFLUX DISEASE: Treatment of symptoms and healing of mucosal lesions; maintenance treatment of reflux oesophagitis. DYSPEPSIA: Treatment of symptoms such as epigastric pain, early satiety, bloating and belching where organic disease has been excluded. IMPAIRED GASTRIC EMPTYING: Relief of the symptoms such as epigastric pain, early satiety, anorexia, bloating and nausea associated with delayed gastric emptying secondary to systemic sclerosis and autonomic neuropathy in diabetes. Dosage and Administration: Adults and children twelve years and over: Take 15 minutes before food. GASTRO-OESOPHAGEAL REFLUX DISEASE: 20mg Prepulsid bd (before breakfast and at bedtime) or 10mg Prepulsid bd if necessary, and this symptoms can be treated with a fourth 10mg dose at bedtime for 12 weeks to heal oesophagitis. For long term maintenance therapy, 20mg once daily (at bedtime) or 10mg twice daily (before breakfast and at bedtime) increasing to 20mg twice daily in patients whose lesions were initially very severe. DYSPEPSIA: 10mg Prepulsid tid. Usual course of treatment is 4 weeks. IMPAIRED GASTRIC EMPTYING: 10mg Prepulsid tid or qd. An initial course of 6 weeks is recommended but longer treatment may be required. CHILDREN: Not recommended in children under 12. ELDERLY: As for adults, but monitor response. ABNORMAL RENAL/LIVER FUNCTION: Initial dose should be halved. Contra-indications: Pregnancy; patients in whom gastrointestinal stimulation might be dangerous; hypersensitivity to Prepulsid. Warnings: Not recommended whilst breast feeding. Drug Interactions: Absorption from the stomach of concomitantly administered drugs may be diminished, whereas absorption of drugs from the small intestine may be accelerated. For drugs that require careful individual titration e.g. anticonvulsants, it may be useful to measure plasma concentrations. In patients

receiving anticoagulants, check prothrombin time as it may be increased. The sedative effects of benzodiazepines and alcohol may be accelerated when given with Prepulsid. The effects of Prepulsid are antagonised by anticholinergic drugs. Side Effects: Abdominal cramps, belching and gas may occur, but are usually transient. Should severe abdominal cramps occur with single administrations of 20mg Prepulsid, halve the dose per administration and double the frequency of dosing. Less frequent side-effects include headaches and lightheadedness. Reports of hypersensitivity, convulsions, extrapyramidal effects and increased urinary frequency have been received. Exceptionally reversible liver function abnormalities have been reported - causal relationship not established. Overdosage: Treatment includes activated charcoal, close observation and general supportive measures. Presentation: Prepulsid Tablets: packs of 120 tablets each containing 10mg cisapride. Prepulsid Suspension: 500ml bottle containing cisapride 500mg. Pharmaceutical Precautions: Prepulsid Tablets: store at room temperature in a dry place, protected from light. Prepulsid Suspension: store at room temperature (below 25°C). PL Number: Tablets PL0242/0130. Prepulsid Suspension PL 0242/0157. PL Holder: Janssen-Cilag Ltd, Beerden, High Wycombe, Bucks, HP14 4UJ. Basic NHS Cost: 120 tablets - £27.00; 500ml bottle suspension - £13.00. Legal Category: POM. References: 1. Janssens J. Effect of cisapride on oesophageal motility. In Johnson A.G., Lux G. Eds. Progress in the treatment of gastrointestinal motility disorders. The role of cisapride. Amsterdam, Excerpta Medica 1988,11-18. 2. DeMaesseneer J. Two different dose regimens of cisapride in the treatment of reflux oesophagitis. In Johnson A.G., Lux G. Eds. Aliment Pharmacol Ther 1993; 7: 409-415. TM - THE MARK OF PREPARATION, December 1994